Maximum obligation under collaborative arrangements.

No definition available.

Name:	shpgf_CollaborativeArrangementConditionalObligationMaximum
Namespace Prefix:	shpgf_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Up-front payment in collaboration arrangement for technology access and R&D funding.

+ References

No definition available.

+ Details

Name:	shpgf_CollaborativeArrangementUpfrontPayment
Namespace Prefix:	shpgf_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Finite-Lived Intangible Asset, Exercise Period

+ References

No definition available.

+ Details

Name:	shpgf_FiniteLivedIntangibleAssetExercisePeriod
Namespace Prefix:	shpgf_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	shpgf_Optionexercisefee
Namespace Prefix:	shpgf_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Payment made for collaboration arrangement during period.

+ References

No definition available.

+ Details

Name:	shpgf_PaymentsToCollaborators
Namespace Prefix:	shpgf_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments to Terminate Collaborative Agreement

+ References

No definition available.

+ Details

Name:	shpgf_PaymentstoTerminateCollaborativeAgreement
Namespace Prefix:	shpgf_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum receivable from collaborators in certain collaborative arrangements.

+ References

No definition available.

+ Details

Name:	shpgf_ReceivableFromCollaboratorsMaximum
Namespace Prefix:	shpgf_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=shpgf_OutLicensingArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	shpgf_CollaborativeArrangementConditionsAxis=shpgf_DevelopmentMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	shpgf_CollaborativeArrangementConditionsAxis=shpgf_SalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	shpgf_CollaborativeArrangementbyPartnerAxis=shpgf_CollaborationWithPrecisionBiosciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=shpgf_InLicensingArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	shpgf_CollaborativeArrangementConditionsAxis=shpgf_ConditionThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	shpgf_CollaborativeArrangementbyPartnerAxis=shpgf_ResearchCollaborationWithSymphogenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	shpgf_CollaborativeArrangementbyPartnerAxis=shpgf_LicenseAgreementWithMerrimackPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	shpgf_CollaborativeArrangementbyPartnerAxis=shpgf_AgreementWithSfjPharmaceuticalsIxLpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=shpgf_PfizerIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=shpgf_SFJPharmaceuticalsGroupMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_BaxaltaIncorporatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=shpgf_OptiontoObtainExclusiveLicensingRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=shpgf_MomentaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative and Other Licensing Arrangements (Narrative) (Details) € in Millions			1 Months Ended				12 Months Ended
	Jun. 03, 2016 USD ($)	Jun. 03, 2016 EUR (€)	Jan. 31, 2017 USD ($)	Sep. 30, 2016 USD ($)	Jul. 31, 2016 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Jun. 03, 2016 EUR (€)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Option exercise fee, for each protein \| €										€ 20.0
Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments received							$ 10,500,000	$ 19,600,000
Out-licensing Arrangement \| Development Milestone
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payment receivable							10,300,000
Out-licensing Arrangement \| Sales Milestone
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payment receivable							15,700,000
Other Revenues \| Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenues recognized							17,400,000	8,900,000	$ 16,700,000
Product Sales \| Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenues recognized							$ 63,000,000	$ 51,000,000	$ 46,500,000
Collaboration with Precision BioSciences \| In-licensing Arrangement \| Certain Success Criteria, and Development and Sales Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum conditional obligation						$ 1,500,000,000.0
Research Collaboration with Symphogen \| In-licensing Arrangement \| Certain Success Criteria, and Development and Sales Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment \| €		€ 1,200.0
License Agreement with Merrimack Pharmaceuticals \| Out-licensing Arrangement \| Certain Success Criteria, and Development and Sales Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment	$ 638,000,000
Agreement with SFJ Pharmaceuticals IX, L.P.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fair value of assumed contingency	$ 288,600,000
Pfizer Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment					$ 90,000,000
SFJ Pharmaceuticals Group
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to terminate agreement				$ 288,000,000
Minimum \| Pfizer Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment					75,000,000
Maximum \| Pfizer Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment					$ 460,000,000
Baxalta \| Option to Obtain Exclusive Licensing Rights
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Exercise period after protein is ready for Phase 2 clinical trials						90 days
Subsequent Event \| Momenta Pharmaceuticals \| Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment			$ 51,200,000